Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy

Circulation

Volumn 119, Issue 9, 2009, Pages 1241-1252

  Suckau, Lennart ^a   Fechner, Henry ^a   Chemaly, Elie ^b   Krohn, Stefanie ^a   Hadri, Lahouaria ^b   Kockskamper, Jens ^c   Westermann, Dirk ^a   Bisping, Egbert ^c   Ly, Hung ^b   Wang, Xiaomin ^a   Kawase, Yoshiaki ^b   Chen, Jiqiu ^b   Liang, Lifan ^b   Sipo, Isaac ^a   Vetter, Roland ^a   Weger, Stefan ^a   Kurreck, Jens ^d   Erdmann, Volker ^d   Tschope, Carsten ^a   Pieske, Burkert ^c   Lebeche, Djamel ^b   Schultheiss, Heinz Peter ^a   Hajjar, Roger J ^b   Poller, Wolfgang C ^a   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Gene therapy; Heart failure; Hypertrophy; MicroRNAs; RNA interference

Indexed keywords

ADENOASSOCIATED VIRUS 9 VECTOR; ADENOVIRUS VECTOR; BETA ACTIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GREEN FLUORESCENT PROTEIN; MICRORNA; PARVOVIRUS VECTOR; PHOSPHOLAMBAN; PROTEIN SERCA2A; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SHORT HAIRPIN RNA; SODIUM CALCIUM EXCHANGE PROTEIN; UNCLASSIFIED DRUG; CALCIUM; CALCIUM BINDING PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; GENE SILENCING; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE FILLING PRESSURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RNA INTERFERENCE; SYSTOLE; TREATMENT RESPONSE; VIRAL GENE THERAPY; ADENOVIRUS; ANIMAL; AORTA; CARDIOMEGALY; CELL CULTURE; CYTOLOGY; DISEASE MODEL; ECHOCARDIOGRAPHY; ECHOGRAPHY; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ADENOVIRIDAE; ANIMALS; AORTA; CALCIUM; CALCIUM-BINDING PROTEINS; CARDIOMEGALY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; GENE THERAPY; GENETIC VECTORS; HEART FAILURE; MICRORNAS; MYOCYTES, CARDIAC; RATS; RATS, WISTAR; RNA INTERFERENCE;

EID: 63649117394     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.783852     Document Type: Article

References (38)

1. 2+-ATPase activity and phosphorylation level of phospholamban. Am J Physiol. 1999;277: H474-H480.
2. MacLennan D, Kranias E. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003;4:566-576.
3. Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date M, Gu Y, Iwatate M, Li M, Wang L, Wilson J, Wang Y, Ross J, Chien K. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med. 2002;8:864-871.
4. Iwanaga Y, Hoshijima M, Gu Y, Iwatate M, Dieterle T, Ikeda Y, Date MO, Chrast J, Matsuzaki M, Peterson KL, Chien KR, Ross J Jr. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest. 2004;113: 727-736.
5. Eizema K, Fechner H, Bezstarosti K, Schneider-Rasp S, van der Laarse A, Wang H, Schultheiss H-P, Poller W, Lamers J. Adenovirus-based phospholamban-antisense-mRNA expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter. Circulation. 2000;101:2193-2199.
6. Dieterle T, Meyer M, Gu Y, Belke DD, Swanson E, Iwatate M, Hollander J, Peterson KL, Ross J Jr, Dillmann WH. Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure. Cardiovasc Res. 2005;67:678-688.
7. Meyer M, Belke DD, Trost SU, Swanson E, Dieterle T, Scott B, Cary SP, Ho P, Bluhm WF, McDonough PM, Silverman GJ, Dillmann WH. A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation. FASEB J. 2004;18:1312-1314.
8. Minamisawa S, Hoshijima M, Chu G, Ward C, Frank K, Gu Y, Martone M, Wang Y, Ross J, Kranias E, Giles W, Chien K. Genetic complementation identifies chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction as a critical calcium cycling defect in the progression of dilated cardiomyopathy. Cell. 1999;99:313-322.
9. 2+ uptake into rat cardiac myocyte sarcoplasmic reticulum. J Mol Cell Cardiol. 2004;37:691-698.
10. Fechner H, Suckau L, Kurreck J, Sipo I, Wang X, Pinkert S, Loschen S, Rekittke J, Weger S, Dekkers D, Vetter R, Erdmann V, Schultheiss H-P, Paul M, Lamers J, Poller W. Highly efficient and specific modulation of cardiac calcium homeostasis by adenovector-derived short hairpin RNA targeting phospholamban. Gene Ther. 2007;14:211-218.
11. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski R, Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999;6:973-985.
12. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth A, Tsuchihashi T, McManus M, Schwartz R, Srivastava D. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell. 2007;129:303-317.
13. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton N, Elia L, Latronico M, Hoydal M, Autore C, Russo MA, Dorn G II, Ellingsen O, Ruiz-Lozano P, Peterson K, Croce C, Peschle C, Condorelli G. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13:613-618.
14. van Rooij E, Sutherland L, Qi X, Richardson J, Hill J, Olson E. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007;316:575-579.
15. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, Wang H, Chen G, Wang Z. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med. 2007;13:486-491.
16. van Rooij E, Sutherland L, Liu N, Williams A, McAnally J, Gerard R, Richardson J, Olson E. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA. 2006;103:18255-18260.
17. Hajjar R, Schmidt U, Matsui T, Guerrero J, Lee K-H, Gwathmey J, Dec G, Semigran M, Rosenzweig A. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA. 1998;95: 5251-5256.
18. del Monte F, Lebeche D, Guerrero JL, Tsuji T, Doye AA, Gwathmey JK, Hajjar RJ. Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci USA. 2004;101:5622-5627.
19. Sakata S, Lebeche D, Sakata N, Sakata Y, Chemaly ER, Liang LF, Tsuji T, Takewa Y, Del Monte F, Peluso R, Zsebo K, Jeong D, Park WJ, Kawase Y, Hajjar R. Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol. 2007;42:852-861.
20. Sakata S, Lebeche D, Sakata Y, Sakata N, Chemaly ER, Liang L, Nakajima-Takenaka C, Tsuji T, Konishi N, del Monte F, Hajjar RJ, Takaki M. Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am J Physiol Heart Circ Physiol. 2007;292:H1204-H1207.
21. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441: 537-541.
22. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake L, Doevendans P, Mummery C, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 2007;116:258-267.
23. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J, Xiao X. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol. 2005;23:321-328.
24. Gregorevič P, Blankinship M, Allen J, Crawford R, Meuse L, Miller D, Russell D, Chamberlain J. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med. 2004;10:828-834.
25. Inagaki K, Fuess S, Storm T, Gibson G, McTiernan C, Kay M, Nakai H. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther. 2006;14:45-53.
26. Pačak C, Mah C, Thattaliyath B, Conlon T, Lewis M, Cloutier D, Zolotukhin I, Tarantal A, Byrne B. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res. 2006;99:e3-e9.
27. Andino LM, Takeda M, Kasahara H, Jakymiw A, Byrne B, Lewin A. AAV-mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes. J Gene Med. 2008;10:132-142.
28. Li J, Hu SJ, Sun J, Zhu ZH, Zheng X, Wang GZ, Yao YM, Chen NY, Zhao XY. Construction of phospholamban antisense RNA recombinant adeno-associated virus vector and its effects in rat cardiomyocytes. Acta Pharmacol Sin. 2005;26:51-55.
29. Champion HC, Georgakopoulos D, Haldar S, Wang L, Wang Y, Kass D. Robust adenoviral and adeno-associated viral gene transfer to the in vivo murine heart: application to study of phospholamban physiology. Circulation. 2003;108:2790-2797.
30. Sakata S, Lebeche D, Sakata Y, Sakata N, Chemaly ER, Liang LF, Padmanabhan P, Konishi N, Takaki M, del Monte F, Hajjar R. Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer. Mol Ther. 2006; 13: 987-996.
31. Lowes B, Gilbert E, Abraham W, Minobe WA, Larrabee P, Ferguson D, Wolfel E, Lindenfeld J, Tsvetkova T, Robertson A, Quaife R, Bristow M. Myocardial gene expression in dilated cardiomyopathy treated with β-blocking agents. N Engl J Med. 2002;346:1357-1365.
32. Ding Z, Georgiev P, Thony B. Administration-route and gender- independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer. Gene Ther. 2006;13: 587-593.
33. Schmitt J, Kamisago M, Asahi M, Li G, Ahmad F, Mende U, Kranias E, MacLennan D, Seidman J, Seidman C. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science. 2003;299: 1410-1413.
34. Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch R, Fan G, Tsiapras D, Parekh R, Dorn G II, MacLennan D, Kremastinos D, Kranias E. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci USA. 2006;103:1388-1393.
35. 2+-ATPase superinhibition and cardiac remodeling. Circulation. 2006;113:995-1004.
36. 2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest. 2006; 116:675-682.
37. 2+ in the heart: contraction versus intracellular signaling. J Clin Invest. 2006;116:623-626.
38. 2+ stores. J Cell Sci. 2008;121:186-195.